Intratumoral Holmium Microspheres Brachytherapy for Patients With Pancreatic Cancer (SLOTH-1)

  • End date
    Dec 22, 2022
  • participants needed
  • sponsor
    Radboud University Medical Center
Updated on 22 March 2022
resectable pancreatic cancer


This is a feasibility study in which patients with pancreatic cancer are treated with intratumoral holmium microsphere injections.

Condition Pancreas Cancer
Treatment QuiremSpheres®
Clinical Study IdentifierNCT05191498
SponsorRadboud University Medical Center
Last Modified on22 March 2022


Yes No Not Sure

Inclusion Criteria

Female or male aged 18 years and over
Diagnosis of primary (borderline) resectable pancreatic cancer by Dutch Pancreatic Cancer Group (DPCG) guidelines
1o-90o contact between tumor and the superior mesenteric artery, celiac axis or common hepatic artery. Or; ii. 90o-270o contact between tumor and superior mesenteric vein or portal vein, without occlusion
iii. The discussion on resectability has to be made in consensus at
multidisciplinary meetings/discussions and may overrule the above criteria (i
Patient is deemed eligible for surgical resection of the pancreatic cancer, however, during open surgery a more advanced disease than initially anticipated is found and resection is no longer feasible
Life expectancy of 12 weeks or longer
World Health Organisation (WHO) Performance status 0-1
One or more measurable lesions of at least 10 mm in the longest diameter by spiral CT or MRI according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
Negative pregnancy test for women of childbearing potential

Exclusion Criteria

Radiation therapy within the last 4 weeks before the start of study therapy
Calcifications in the pancreas or tumour that are highly expected to obstruct the needle tract
Any unresolved toxicity greater than National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE version 4.0) grade 2 from previous anti-cancer therapy
Leukocytes < 4.0 109/l and/or platelet count < 100 109/l
Significant cardiac event (e.g. myocardial infarction, superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease ≥2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia
Patient is deemed ineligible for implantation of 166Ho by an expert panel (surgeon, nuclear medicine physician and researcher) due to tumour anatomy or nearby structures
Pregnancy or breast feeding (women of child-bearing potential)
Patients suffering from psychic disorders that make a comprehensive judgement impossible, such as psychosis, hallucinations and/or depression
Patients who are declared incompetent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note